Reduce the risk of QT interval prolongation associated with targeted cancer therapy by using arrhythmic risk stratification and prevention strategies

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Drugs & Therapy Perspectives

• Publication date

  2017-07-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/S40267-017-0428-4
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeted Cancer Therapies and QT Interval Prolongation: Unveiling the Mechanisms Underlying Arrhythmic Complications and the Need for Risk Stratification Strategies

  2017cited by this paper
• Shared Risk Factors in Cardiovascular Disease and Cancer

  2016cited by this paper
• Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit

  2015cited by this paper
• Pharmacogenetics of Drug-Induced QT Interval Prolongation: An Update

  2015cited by this paper
• Adverse reactions to oncologic drugs: spontaneous reporting and signal detection

  2015cited by this paper
• QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review

  2015cited by this paper
• QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors

  2014cited by this paper
• Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP Channel

  2013cited by this paper
• Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines.

  2012cited by this paper
• Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials.

  2011cited by this paper
• Drug-Induced Long QT Syndrome

  2010cited by this paper
• Prolonged QTc interval in cancer therapeutic drug development: defining arrhythmic risk in malignancy.

  2010cited by this paper
• Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.

  2010cited by this paper
• A Phase I Trial of Enzastaurin in Patients with Recurrent Gliomas

  2009cited by this paper
• Case ascertainment and estimated incidence of drug-induced long-QT syndrome: study in Southwest France.

  2008cited by this paper
• Genetics of acquired long QT syndrome.

  2005cited by this paper
• Poisoning by sodium channel blocking agents.

  1997cited by this paper

• No citing papers are available for this paper.